Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:conditionStudied |
relapsed/refractory multiple myeloma
|
| gptkbp:endPoint |
overall response rate
|
| gptkbp:enrollment |
128
|
| gptkbp:FDAApprovalRelated |
gptkb:Abecma
|
| https://www.w3.org/2000/01/rdf-schema#label |
KarMMa trial
|
| gptkbp:location |
multinational
|
| gptkbp:number |
NCT03361748
|
| gptkbp:period |
Phase 2
|
| gptkbp:principalInvestigator |
gptkb:Nikhil_Munshi
|
| gptkbp:publishedResults |
NEJM 2021
|
| gptkbp:sponsor |
gptkb:bluebird_bio
gptkb:Bristol_Myers_Squibb |
| gptkbp:startYear |
2017
|
| gptkbp:studiedTreatment |
gptkb:idecabtagene_vicleucel
|
| gptkbp:treatment |
gene therapy
|
| gptkbp:bfsParent |
gptkb:Chimeric_Antigen_Receptor_T-cell_therapy
|
| gptkbp:bfsLayer |
8
|